


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. **(currently amended)** A compound of formula (I):



wherein R^1 represents C1-6 alkyl which may have optionally protected hydroxy, C1-6 alkyl which may have optionally protected mercapto, C1-6 alkyl which may have optionally substituted cyclic group, C2-6 alkenyl which may have optionally protected hydroxy, C2-6 alkenyl which have optionally protected mercapto, C2-6 alkynyl which may have optionally substituted cyclic group, C2-6 alkynyl which may have optionally protected hydroxy, C2-6 alkynyl which may have optionally protected mercapto, or C2-6 alkynyl which may optionally substituted cyclic group ~~aliphatic hydrocarbon optionally having substituent(s),~~

ring A represents a ~~cyclic piperidine group comprising at least one nitrogen atom~~ optionally having further substituent(s) one or more substituents besides R^1 selected from the group consisting of (a) optionally substituted alkyl, (b) optionally substituted alkenyl, (c) optionally substituted alkynyl, (d) an optionally substituted carbocyclic ring, (e) an optionally substituted heterocyclic ring, (f) optionally protected hydroxy, (g) optionally protected mercapto, (h) optionally substituted amino, (i) optionally substituted carbamoyl, (j) optionally substituted sulfamoyl, (k) carboxy, (l) alkoxycarbonyl, (m) sulfo ($-\text{SO}_3\text{H}$), (n) sulfinio, (o) phosphono, (p)

nitro, (q) thioxo, (r) cyano, (s) amidino, (t) imino, (u) -B(OH)₂, (v) a halogen atom, (w) alkylsulfinyl, (x) arylsulfinyl, (y) alkylsulfonyl, (z) arylsulfonyl, and (aa) acyl,

ring B represents a ~~cyclic-phenyl~~ group optionally having substituent(s)one or more substituents and is attached to ring A via a bond,

G represents ~~a bond or a spacer~~ an alkylene group comprising 1-4 atoms in the main chain,

J represents ~~a spacer having a hydrogen bond accepting~~ an amide group optionally having substituent(s)one or more substituents,

K represents ~~a bond or a spacer comprising 1-4 atoms in the main chain, and~~

ring D represents a ~~cyclic-phenyl~~ group optionally having substituent(s)one or more substituents, which may form a ring together with a substituent on J,

a salt thereof, or an N-oxide thereof, ~~a solvate thereof or a prodrug thereof.~~

2. **(canceled).**

3. **(currently amended)** The compound according to claim 1,


wherein J is ~~-CO-, -CONR²-, -NR²CO-, -OCO-, -COO-, -CS-, -CSNR²-, -NR²CS-, -O-CS-, -CS-O-, -SO₂-, -SO₂NR²-, -NR²SO₂-, -O-SO₂-, -SO₂-O-, -S(O)-, -S(O)NR²-, -NR²S(O)-, -O-S(O)-, -S(O)-O-, or -C(=NR³)-,~~

wherein R² represents a hydrogen atom, ~~optionally substituted aliphatic hydrocarbon or an optionally substituted cyclic group~~ and R³ represents a hydrogen atom, ~~cyano, optionally protected hydroxy, optionally substituted amino, optionally substituted aliphatic hydrocarbon or an optionally substituted cyclic group,~~

a salt thereof, ~~or an N-oxide thereof, a solvate thereof or a prodrug thereof.~~

4.-8 (canceled).

9. (currently amended): A pharmaceutical composition comprising a compound of formula (I)



wherein R¹ represents C1-6 alkyl which may have optionally protected hydroxy, C1-6 alkyl which may have optionally protected mercapto, C1-6 alkyl which may have optionally substituted cyclic group, C2-6 alkenyl which may have optionally protected hydroxy, C2-6 alkenyl which may have optionally protected mercapto, C2-6 alkenyl which may have optionally substituted cyclic group, C2-6 alkynyl which may have optionally protected hydroxy, C2-6 alkynyl which may have optionally protected mercapto, or C2-6 alkynyl which may have optionally substituted cyclic group ~~aliphatic hydrocarbon optionally having substituent(s),~~

ring A represents a ~~cyclic piperidine group comprising at least one nitrogen atom~~ optionally having further substituent(s) one or more substituents besides R¹, selected from the group consisting of (a) optionally substituted alkyl, (b) optionally substituted alkenyl, (c) optionally substituted alkynyl, (d) an optionally substituted carbocyclic ring, (e) an optionally substituted heterocyclic ring, (f) optionally protected hydroxy, (g) optionally protected mercapto, (h) optionally substituted amino, (i) optionally substituted carbamoyl, (j) optionally substituted sulfamoyl, (k) carboxy, (l) alkoxycarbonyl, (m) sulfo (-SO₃H), (n) sulfinio, (o) phosphono, (p)

nitro, (q) thioxo, (r) cyano, (s) amidino, (t) imino, (u) -B(OH)₂, (v) a halogen atom, (w) alkylsulfinyl, (x) arylsulfinyl, (y) alkylsulfonyl, (z) arylsulfonyl, and (aa) acyl,

ring B represents a ~~eyelic-phenyl~~ group optionally having substituent(s)one or more substituents and is attached to ring A via a bond,

G represents a ~~bond or a spacer~~an alkylene group comprising 1-4 atoms in the main chain,

J represents a ~~spacer having a hydrogen bond accepting~~an amide group optionally having substituent(s)one or more substituents,

K represents a ~~bond or a spacer comprising 1-4 atoms in the main chain~~, and

ring D represents a ~~eyelic-phenyl~~ group optionally having substituent(s)one or more substituents, which may form a ring together with a substituent on J,

a salt thereof,or an N-oxide thereof, a ~~solvate thereof or a prodrug thereof~~, and a pharmaceutically acceptable carrier or diluent.

10. **(Original)** The composition according to claim 9, which is a chemokine receptor antagonist.

11. **(Original)** The composition according to claim 10, wherein the chemokine receptor is CCR1.

12. **(Original)** The composition according to claim 10, wherein the chemokine receptor is CCR5.

13. **(Original)** The composition according to claim 10, which is a medicament for the prevention and/or treatment of human immunodeficiency virus infectious disease, acquired immunodeficiency syndrome and/or organ rejection in transplantation.

14. **(currently amended)** The composition according to claim 10, which is a medicament for the ~~prevention and/or~~ treatment of multiple sclerosis and/or arthritis.

15. **(currently amended)** A method for the ~~prevention and/or~~ treatment of asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, organ rejection in transplantation, immunosuppression, psoriasis, multiple sclerosis, optic neuritis, polymyalgia rheumatica syndrome, uveitis, vasculitis, human immunodeficiency virus infection, acquired immunodeficiency syndrome, atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, osteoarthritis, ischemic reperfusion injury, acute respiratory distress syndrome, shock accompany bacteria infection, diabetes, cancer metastasis or atherosclerosis ~~diseases induced by a chemokine receptore~~ in a mammal, which comprises administering to ~~an~~ a mammal an effective amount of the compound according to claim 1, a salt thereof, or ~~an N-oxide thereof, a solvate thereof or a prodrug thereof.~~

16. **(canceled).**

17. **(currently amended)** A medicament comprising the compound according to claim 1, a salt thereof, or ~~an N-oxide thereof, a solvate thereof or a prodrug thereof,~~ and one or more selected from the group consisting of a protease inhibitor, a reverse transcriptase inhibitor, a

fusion inhibitor, an HIV integrase inhibitor, a chemokine inhibitor, a steroidal drug, interferon, an immunosuppressant, an aldose reductase inhibitor, a cannabinoid-2 receptor agonist, adrenocorticotrophic hormone, a metalloproteinase inhibitor, a non-steroidal anti-inflammatory drug, a prostaglandin drug, a phosphodiesterase inhibitor, a disease modifying anti-rheumatic drug, an anti-inflammatory enzyme drug, a cartilage-protecting drug, a T-cell inhibitor, a TNF- α inhibitor, an IL-6 inhibitor, an interferon γ agonist, an IL-1 inhibitor and an NF- κ B inhibitor.

18. **(new)**: A method for the treatment of a disease, which comprises administering to a mammal an effective amount of a medicament comprising the compound according to claim 1, a salt thereof, an N-oxide thereof, and one or more selected from the group consisting of a protease inhibitor, a reverse transcriptase inhibitor, a fusion inhibitor, an HIV integrase inhibitor, a chemokine inhibitor, a steroidal drug, interferon, an immunosuppressant, an aldose reductase inhibitor, a cannabinoid-2 receptor agonist, adrenocorticotrophic hormone, a metalloproteinase inhibitor, a non-steroidal anti-inflammatory drug, a prostaglandin drug, a phosphodiesterase inhibitor, a disease modifying anti-rheumatic drug, an anti-inflammatory enzyme drug, a cartilage-protecting drug, a T-cell inhibitor, a TNF- α inhibitor, an IL-6 inhibitor, an interferon γ agonist, an IL-1 inhibitor and an NF- κ B inhibitor.